We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute
News

LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute

LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute
News

LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.

“With the addition of DHMRI’s discovery capabilities, LabCorp offers its clinical trials clients the most complete suite of biomarker development tools in the industry,” said Dr. David Johnston, Senior Vice President and Global Head of Clinical Trials at LabCorp. “Our collaboration with DHMRI exemplifies our strong commitment to providing cutting-edge services to our clients,” said Dr. Johnston.

The services available to clients through DHMRI include broad biomarker discovery and proof of concept assay development to support early and late stage drug discovery and development. DHMRI uses trans-disciplinary approaches to provide solutions for customers. DHMRI has capabilities and expertise ranging from profiling at the genetic, biochemical, cellular and in vivo levels to clinical immune system monitoring using multiparameter flow cytometry and multiplexed protein analysis and quantitative gene expression.

Advertisement